PD
OVID icon

Point72 (DIFC)’s Ovid Therapeutics OVID Stock Holding History

Point72 (DIFC)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$256 Sell
197
-1,104
-85% -$957 ﹤0.01% 1103
2025
Q2 		$429 Buy
+1,301
New +$392 ﹤0.01% 1471

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Point72 (DIFC)'s OVID Position: Q3 2025 in Review

Point72 (DIFC) reduced its Ovid Therapeutics (OVID) stake by 85% in Q3 2025, selling an estimated $957 and leaving 197 shares worth $256. The position accounts for ﹤0.01% of the portfolio, ranked #1103.

Point72 (DIFC) first reported a position in OVID in Q2 2025 and has held it in 2 quarters since. The position peaked at $429 in Q2 2025. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • Point72 (DIFC) held 197 shares of Ovid Therapeutics worth $256 as of Q3 2025.
  • Point72 (DIFC) sold 1,104 Ovid Therapeutics shares in Q3 2025, an estimated $957.
  • Ovid Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1103 holding.
  • Point72 (DIFC) first reported a position in Ovid Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s Ovid Therapeutics position peaked at $429 in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.